Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model.

Experimental neurology - 1 Mar 2007

Grunfeld Jonathan F, Barhum Yael, Blondheim Netta, Rabey Jose-Martin, Melamed Eldad, Offen Daniel

Abstract excerpt

Erythropoietin (Epo) has been shown in the recent years to have neuroprotective activity in a variety of settings. In this study, we investigated its impact on the progression of paralysis in a mouse model simulating the human disorder amyotrophic lateral sclerosis (ALS). We found that Epo can delay the onset of motor deterioration in transgenic SOD G93A mice without prolonging their survival. Notably this effect...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Erythropoietin
Share to Guanine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Injections, Intraperitoneal

Share to Motor Neurons

Share to Neuroprotective Agents

Share to Spinal Cord

Share to Superoxide Dismutase-1

Source

Identifiers

PMID: 17174305
DOI: 10.1016/j.expneurol.2006.11.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model.PMID 17174305Read ↗

Recombinant human erythropoietin reduces aggregation of mutant Cu/Zn-binding superoxide dismutase (SOD1) in NSC-34 cells.Semantic proximity Read ↗

Lentiviral delivery of human erythropoietin attenuates hippocampal atrophy and improves cognition in the R6/2 mouse model of Huntington's diseaseSemantic proximity Read ↗

Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson's diseaseSemantic proximity Read ↗

Transient caloric restriction in early adulthood hastens disease endpoint in male, but not female, Cu/Zn-SOD mutant G93A mice.Semantic proximity Read ↗

Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS.Semantic proximity Read ↗

Behavioural and anatomical effects of systemically administered leukemia inhibitory factor in the SOD1(G93A G1H) mouse model of familial amyotrophic lateral sclerosis.Semantic proximity Read ↗

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.Semantic proximity Read ↗

From Erythropoiesis to Circuit Rewiring: Erythropoietin as a Precision Tool for NeurorestorationSemantic proximity Read ↗

Identification of early disease progression in an ALS rat model.Semantic proximity Read ↗

Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease.Semantic proximity Read ↗

Autoimmune anemia in macaques following erythropoietin gene therapySemantic proximity Read ↗

Erythropoietin reduces the expression of myostatin in mdx dystrophic mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.